Factory supply 99% 167933-07-5 flibanserin powder
1.Competitive price
2.Fast Delivery Within 2 days
3.SGS , BV, GMP,ISO approve
4.Professional factory
Flibanserin
| Product Name | Flibanserin |
| CAS.NO. | 167933-07-5 |
| Molecular Weight | 390.4021 g/mol |
| Molecular Formula | C20H21F3N4O |
| Standard | EnterpriseStandard |
| Abstract | HSDD |
| Testing Items | Specifications | Results |
| Characteristics | An off-white to white powder | Complied |
| Identification | Meet the requirements | Positive |
| Loss on Drying | ≤0.50% | 0.13% |
| Heavy Metals | ≤20PPM | <20PPM |
| Purity (by HPLC) | ≥99.0% | 99.2% |
| Conclusion: | The commodity is complied with the standard of the factory |
|
1)Product Name:Flibanserin
2) Specification: ≥99.0%
3) Testing Method: HPLC
4) Appearance: White fine powder
5) Introduction:
Flibanserin;Bimt 17;3-[2-[4-[4-(Trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2 one;Filbanserin;Flibanerins Flibanserin HCL (INN, USAN) (developmental code name BIMT-17; proposed trade names Girosa and Addyi) is a drug that is being studied as a non-hormonal treatment for pre-menopausal women with hypoactive sexual desire disorder (HSDD). Development by Boehringer Ingelheim was halted in October 2010 following a negative evaluation by the U.S. Food and Drug Administration. The rights to the drug were then transferred to Sprout Pharmaceuticals, which is continuing the drug development process.
China
